Combining Gilead’s Ambrisentan and Tadalafil in PAH Clinical Trial Reduced Risk of Clinical Failure
When Gilead Sciences, Inc. initiated a clinical trial for first-line combination therapy for pulmonary arterial hypertension treatment, the company felt that their ambitious approach to developing a new, viable therapy for the disease was worthy of the clinical trial name “AMBITION.” Now, according to a…